PAVmed (PAVM) Common Equity (2015 - 2026)

PAVmed has reported Common Equity for 12 years, with the latest figure at $35.0 million in Q2 2026.

• On a quarterly basis, Common Equity rose 24.46% year-over-year to $35.0 million in Q2 2026; TTM through Jun 2026 was $35.0 million, a 24.46% increase from a year earlier, with the FY2025 full-year figure at $34.0 million, up 582.97% from the prior year.
• Common Equity was $35.0 million for Q2 2026 at PAVmed, up from $34.0 million in the prior quarter.
• The five-year high for Common Equity was $64.7 million in Q1 2022, with the low at -$24.0 million in Q4 2023.
• Average Common Equity over 5 years is $14.5 million, with a median of $10.9 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Common Equity tumbled 2146.02% in 2024, then surged 582.97% in 2025.
• Over 5 years, Common Equity stood at $10.9 million in 2022, then sank by 319.66% to -$24.0 million in 2023, then soared by 70.72% to -$7.0 million in 2024, then soared by 582.97% to $34.0 million in 2025, then gained by 3.18% to $35.0 million in 2026.
• The last three Common Equity figures came in at $35.0 million (Q2 2026), $34.0 million (Q4 2025), and $32.5 million (Q3 2025), per Business Quant data.